4
Changes in Ownership
Cytek Biosciences, Inc. Filed Acc 0001209191-23-046826
Chief Commercial Officer gave up 1,836 shares (to pay taxes)
- Chief Commercial Officer acquired 4,712 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Garland Jonathan Todd Chief Commercial Officer | 2023-08-18 | Option exercise | +1,951 | 7,838 | D | ||
| Garland Jonathan Todd Chief Commercial Officer | 2023-08-18 | Shares withheld for taxes | −760 | $8.46 | $6,430 | 7,078 | D |
| Garland Jonathan Todd Chief Commercial Officer | 2023-08-18 | Option exercise | +2,761 | 9,839 | D | ||
| Garland Jonathan Todd Chief Commercial Officer | 2023-08-18 | Shares withheld for taxes | −1,076 | $8.46 | $9,103 | 8,763 | D |
| Derivatives | |||||||
| Garland Jonathan Todd Chief Commercial Officer | 2023-08-18 | Option exercise · Restricted Stock Units | −1,951 | 21,462 | D | ||
| Garland Jonathan Todd Chief Commercial Officer | 2023-08-18 | Option exercise · Restricted Stock Units | −2,761 | 39,579 | D | ||
Loading xslF345X05/doc4.xml…